Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
Francis J. Giles, Jorge E. Cortes, Deborah A. Thomas, Guillermo Garcia-Manero, Stephan Faderl, Sima Jeha, Robert L. De Jager, Hagop M. Kantarjian
Dive into the research topics of 'Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia'. Together they form a unique fingerprint.